GlaxoSmithKline, Regulus deal

The companies will add a second Phase II HCV trial to a 2015 deal. In 4Q16, the companies will start a trial combining a long-acting formulation of GlaxoSmithKline’s GSK2878175 with Regulus’ RG-101. The partners expect interim results by year end from the original trial, which is evaluating the combination of oral GSK2878175 and RG-101. The companies will continue to share trial costs and expect data from the new trial in 2H17. GSK declined to disclose details. Regulus did not respond in time for publication. ...